ARGX Stock Analysis: argenx | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 55.915m USD | 12M Return: 72.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 344M
Qual. Beats: 0
Rev. Trend: 97.3%
Qual. Beats: 4
Warnings
No concerns identified
Tailwinds
Seasonality 9.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
argenx SE (NASDAQ: ARGX) is a Netherlands-based, commercial-stage biopharma company focused on developing therapies for autoimmune diseases, with operations spanning the U.S., Japan, China, and Europe. The company markets VYVGART (efgartigimod) for generalized myasthenia gravis (gMG) and immune thrombocytopenia (ITP), along with VYVGART HYTRULO for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP), and is expanding its efgartigimod franchise across multiple autoimmune indications including myositis, Sjögrens disease, and Graves disease. Its broader pipeline features FcRn-targeted antibodies, empasiprubart, adimanebart, and several early-stage candidates (ARGX-213, ARGX-124, ARGX-109, ARGX-121, ARGX-118), supported by strategic partnerships with Zai Lab, Halozyme, OncoVerity, and AbbVie. The company operates within the biotechnology sub-industry, a sector characterized by long development cycles, heavy R&D investment, and reliance on FDA and international regulatory approvals to commercialize rare-disease therapies.
- VYVGART franchise revenue grows on CIDP label expansion
- Pipeline catalysts advance in seronegative gMG and myositis indications
- FcRn competition intensifies as new entrants gain regulatory approvals
| Net Income: 2.00b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 12.16 > 1.0 |
| NWC/Revenue: 84.81% < 20% (prev 116.6%; Δ -31.83% < -1%) |
| CFO/TA 0.10 > 3% & CFO 850.5m > Net Income 2.00b |
| Net Debt (-4.31b) to EBITDA (1.83b): -2.36 < 3 |
| Current Ratio: 5.23 > 1.5 & < 3 |
| Outstanding Shares: last quarter (66.2m) vs 12m ago 13.59% < -2% |
| Gross Margin: 89.65% > 18% (prev 76.52%; Δ 13.12% > 0.5%) |
| Asset Turnover: 88.39% > 50% (prev 58.24%; Δ 30.15% > 0%) |
| Interest Coverage Ratio: 436.7 > 6 (EBIT TTM 1.80b / Interest Expense TTM 4.12m) |
| A: 0.64 (Total Current Assets 6.90b - Total Current Liabilities 1.32b) / Total Assets 8.68b |
| B: -0.03 (Retained Earnings -279.8m / Total Assets 8.68b) |
| C: 0.24 (EBIT TTM 1.80b / Avg Total Assets 7.44b) |
| D: 5.39 (Book Value of Equity 7.32b / Total Liabilities 1.36b) |
| Altman-Z'' = 11.39 = AAA |
| DSRI: 1.00 (Receivables 1.66b/909.1m, Revenue 6.58b/3.61b) |
| GMI: 0.85 (GM 76.52% / 89.65%) |
| AQI: 0.97 (AQ_t 0.20 / AQ_t-1 0.21) |
| SGI: 1.82 (Revenue 6.58b / 3.61b) |
| TATA: 0.13 (NI 2.00b - CFO 850.5m) / TA 8.68b) |
| Beneish M = -2.57 (Cap -4..+1) = A |
As of July 06, 2026, the stock is trading at USD 939.68 with a total of 381,200 shares traded. Over the past week, the price has changed by +5.74%, over one month by +5.43%, over three months by +25.58% and over the past year by +72.09%.
Current recommended Stop Loss: 902.10 (which is 4% or 1.2 ATR below the current price).
argenx has received a consensus analysts rating of 4.59. Therefore, it is recommended to buy ARGX.
- StrongBuy: 14
- Buy: 7
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 1044.6 | 11.2% |
P/E Trailing = 39.7649
P/E Forward = 34.0136
P/S = 11.691
P/B = 7.5222
P/EG = 1.5103
Revenue TTM = 6.58b USD
EBIT TTM = 1.80b USD
EBITDA TTM = 1.83b USD
Long Term Debt = 72.7m USD (estimated: total debt 83.5m - short term 10.8m)
Short Term Debt = 10.8m USD (from shortTermDebt, last quarter)
Debt = 130.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 47.2m
Net Debt = -4.31b USD (calculated: Debt 130.6m - CCE 4.44b)
Enterprise Value = 51.6b USD (55.9b + Debt 130.6m - CCE 4.44b)
Interest Coverage Ratio = 436.7 (Ebit TTM 1.80b / Interest Expense TTM 4.12m)
EV/FCF = 61.12x (Enterprise Value 51.6b / FCF TTM 844.3m)
FCF Yield = 1.64% (FCF TTM 844.3m / Enterprise Value 51.6b)
FCF Margin = 12.83% (FCF TTM 844.3m / Revenue TTM 6.58b)
Net Margin = 30.44% (Net Income TTM 2.00b / Revenue TTM 6.58b)
Gross Margin = 89.65% ((Revenue TTM 6.58b - Cost of Revenue TTM 681.1m) / Revenue TTM)
Gross Margin QoQ = 90.68% (prev 89.40%)
Tobins Q-Ratio = 5.94 (Enterprise Value 51.6b / Total Assets 8.68b)
Interest Expense / Debt = 3.15% (Interest Expense 4.12m / Debt 130.6m)
Taxrate = 0.65% (13.7m / 2.09b)
NOPAT = 1.79b (EBIT 1.80b * (1 - 0.65%))
Current Ratio = 5.23 (Total Current Assets 6.90b / Total Current Liabilities 1.32b)
Debt / Equity = 0.02 (Debt 130.6m / totalStockholderEquity, last quarter 7.32b)
Debt / EBITDA = -2.36 (Net Debt -4.31b / EBITDA 1.83b)
Debt / FCF = -5.10 (Net Debt -4.31b / FCF TTM 844.3m)
Total Stockholder Equity = 5.79b (last 4 quarters mean from totalStockholderEquity)
RoA = 26.90% (Net Income 2.00b / Total Assets 8.68b)
RoE = 34.55% (Net Income TTM 2.00b / Total Stockholder Equity 5.79b)
RoCE = 30.65% (EBIT 1.80b / Capital Employed (Equity 5.79b + L.T.Debt 72.7m))
RoIC = 25.36% (NOPAT 1.79b / Invested Capital 7.04b)
WACC = 7.04% (E(55.9b)/V(56.0b) * Re(7.05%) + D(130.6m)/V(56.0b) * Rd(3.15%) * (1-Tc(0.01)))
Discount Rate = 7.05% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 58.43 | Cagr: 5.69%
[DCF] Terminal Value 75.44% ; FCFF base≈844.3m ; Y1≈847.8m ; Y5≈898.1m
[DCF] Fair Price = 293.9 (EV 14.0b - Net Debt -4.31b = Equity 18.3b / Shares 62.2m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.56 | # QB: 0
Revenue Correlation: 97.33 | Revenue CAGR: 113.7% | SUE: 0.85 | # QB: 4
EPS current Quarter (2026-06-30): EPS=5.30 | Chg30d=+1.95% | Revisions=+53% | Analysts=14
EPS next Quarter (2026-09-30): EPS=5.87 | Chg30d=+2.03% | Revisions=+13% | Analysts=13
EPS current Year (2026-12-31): EPS=22.31 | Chg30d=+1.56% | Revisions=+39% | GrowthEPS=+34.6% | GrowthRev=+43.9%
EPS next Year (2027-12-31): EPS=32.28 | Chg30d=+1.86% | Revisions=+24% | GrowthEPS=+44.7% | GrowthRev=+21.7%
[Analyst] Revisions Ratio: +38% (up=37, down=16)